SALT LAKE CITY, June 9 GE Healthcare, a unit of the General Electric Company (NYSE: GE), today presented interim phase 2 study results of fluciclatide, in collaboration with the National Cancer Institute (NCI), a federal research agency and part of the National Institutes of Health. Fluciclatide is an integrin-targeted radiopharmaceutical under development for oncology PET imaging. Esther Mena, MD, Associate Investigator at the NCI, presented preliminary data on the uptake and retention properties of fluciclatide in solid tumors at the 57th annual meeting of the Society of Nuclear Medicine in Salt Lake City, Utah.
Advertisement
This phase 2 study is part of a larger multi-site clinical program being conducted in the US, Europe, India and Korea. The goal of the GE Healthcare program is to detect and measure integrin expression in patients with various solid tumor types, including melanoma and renal cell carcinoma.
Advertisement
Dr. Mena presented preliminary data from 10 patients with solid tumors not previously imaged with fluciclatide. Positron emission tomography/computed tomography (PET/CT) imaging of each patient's target lesion was performed for 60 minutes followed by a static whole-body PET/CT scan. The biodistribution of fluciclatide permitted visual analysis of the target lesion as a means to demonstrate variable solid tumor uptake and retention, sometimes with heterogeneous distribution within the tumor. Mean and maximum tumor and blood pool standardized uptake values (SUVmax/mean) were examined in the trial.
"The development of PET radiopharmaceuticals are important to the clinical community who are seeking a diagnostic work-up that only molecular imaging can provide," said Homer Macapinlac, MD, Chair, Nuclear Medicine, University of Texas, M.D. Anderson Cancer Center. "PET tracers may be useful diagnostic tools for oncologists."
About GE Healthcare:
GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.
Our "healthymagination" vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality and efficiency around the world. Headquartered in the United Kingdom, GE Healthcare is a $17 billion unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employs more than 46,000 people committed to serving healthcare professionals and their patients in more than 100 countries. For more information about GE Healthcare, visit our web site at www.gehealthcare.com.
References:
1. Pasqualini R, Koivunen E, Ruoslahti E. Alpha v integrins as receptors for tumor targeting by circulating ligands. Nat Biotechnol.1997;15:542-546.
SOURCE GE Healthcare
